Bildkälla: Stockfoto

Heliospectra Q2 2024: Weaker sales, minor deviations elsewhere - Redeye

Redeye comments on Heliospectra’s Q2 results, noting that sales were weaker than expected due to short-term delays and the timing of orders. However, order intake and operating expenses were in line with our forecast. The key highlight is the optimistic short-term outlook.

Redeye comments on Heliospectra’s Q2 results, noting that sales were weaker than expected due to short-term delays and the timing of orders. However, order intake and operating expenses were in line with our forecast. The key highlight is the optimistic short-term outlook.
Börsvärldens nyhetsbrev
ANNONSER